J
José E. Manautou
Researcher at University of Connecticut
Publications - 105
Citations - 4817
José E. Manautou is an academic researcher from University of Connecticut. The author has contributed to research in topics: Acetaminophen & Liver injury. The author has an hindex of 37, co-authored 93 publications receiving 4077 citations. Previous affiliations of José E. Manautou include University of Arizona & University of Buenos Aires.
Papers
More filters
Journal ArticleDOI
Oxidative and electrophilic stress induces multidrug resistance–associated protein transporters via the nuclear factor‐E2–related factor‐2 transcriptional pathway
Jonathan M. Maher,Matthew Z. Dieter,Lauren M. Aleksunes,Angela L. Slitt,Angela L. Slitt,Grace L. Guo,Yuji Tanaka,George L. Scheffer,Jefferson Y. Chan,José E. Manautou,Ying Chen,Timothy P. Dalton,Masayuki Yamamoto,Curtis D. Klaassen +13 more
TL;DR: The activation of the Nrf2 regulatory pathway stimulates the coordinated induction of hepatic Mrps in mice treated with oltipraz and butylated hydroxyanisole.
Journal ArticleDOI
Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
TL;DR: Research of Nrf2 has opened up new opportunities in understanding how antioxidant defense pathways are regulated, how oxidative stress contributes to disease progression and may serve as a novel target for designing therapies to prevent and treat diseases in which oxidative stress is implicated.
Journal ArticleDOI
Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity
TL;DR: A comprehensive, up-to-date overview of hepatic toxicity as well as a thorough review of both toxic and beneficial effects of APAP in brain are presented.
Journal ArticleDOI
Molecular mechanisms underlying chemical liver injury.
Xinsheng Gu,José E. Manautou +1 more
TL;DR: Research aimed at elucidating the molecular mechanism of the pathogenesis of chemical-induced liver diseases is fundamental for preventing or devising new modalities of treatment for liver injury by chemicals.
Journal ArticleDOI
The growth of siRNA-based therapeutics: Updated clinical studies.
TL;DR: In this paper, the authors provide a brief overview of mechanisms of siRNA action, physiological barriers to its delivery and activity, and the most common chemical modifications and delivery platforms used to overcome these barriers.